Beam Therapeutics
Beam develops investigational precision genetic medicines using base editing. Its website describes a delivery strategy spanning electroporation and nonviral and viral approaches. Those routes include different applications; the platform label alone does not establish in vivo efficacy.
Corporate information
- Company entity
- Beam Therapeutics
- Headquarters / principal office
- Cambridge, MassachusettsSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2017 ↗
- Ownership / capital status
- Publicly tradedPublicly traded (Nasdaq: BEAM); public-market transactions tracked separately ↗
- Official corporate reference
- https://beamtx.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Beam develops investigational precision genetic medicines using base editing. Its website describes a delivery strategy spanning electroporation and nonviral and viral approaches. Those routes include different applications; the platform label alone does not establish in vivo efficacy.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Breaking new ground to advance science with the potential to change lives | Beam Therapeutics
- Beam official science and founding history
- Company-managed LinkedIn profile — self-reported location
- Corporate ownership / financing disclosure